Pediatrix Q4 revenue beats estimates

Pediatrix Medical

19/02/2026 11:08

Overview

Physician services provider's Q4 revenue beat analyst expectations

Adjusted EBITDA for Q4 missed analyst expectations

Same-unit revenue growth driven by improved collections and favorable payor mix

Outlook

Pediatrix anticipates 2026 Adjusted EBITDA between $280 mln and $300 mln

Result Drivers

SAME-UNIT REVENUE GROWTH - Driven by improved collections, favorable payor mix, and higher patient acuity, particularly in neonatology

PRACTICE DISPOSITIONS - Net revenue decline due to practice dispositions, partially offset by same-unit revenue growth

PATIENT SERVICE VOLUME DECLINE - Same-unit patient service volumes decreased by 2.7% in Q4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$493.77 mln
$486.23 mln (7 Analysts)
Q4 Net Income
$33.68 mln
Q4 Adjusted EBITDA
Miss
$65.85 mln
$71.10 mln (7 Analysts)
Q4 Income from operations
$48.79 mln
Q4 Operating Expenses
$444.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Pediatrix Medical Group Inc is $22.00, about 0.1% above its February 18 closing price of $21.97

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nBw99nhjFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)